Meeting
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Immune profiling of circulating T cells and TILs following neoadjuvant ipilimumab and chemotherapy in non-small cell lung cancer (NSCLC).
Authors
John Yi
Duke University Medical Center, Durham, NC
John Yi, Jeffrey Melson Clarke, Patrick Healy, Xiaofei F. Wang, Debra Shoemaker, Mark W. Onaitis, Chelsae Dumbauld, Robyn Osborne, Jeffrey Crawford, David Harpole, Thomas A. D'Amico, Frank Dunphy, Jared Christensen, Neal Ready, Kent Weinhold
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Biomarkers and Inflammatory Signatures,Humoral Immunity for Diagnosis and Therapy,Immune Checkpoints and Stimulatory Receptors,Modulating Innate Immunity,Therapies Targeting T cells
Sub Track
Novel Biomarker Approaches
Clinical Trial Registration Number
NCT01820754
Citation
J Clin Oncol 35, 2017 (suppl 7S; abstract 26)
DOI
10.1200/JCO.2017.35.7_suppl.26
Abstract #
26
Poster Bd #
C9
Abstract Disclosures
Similar Posters
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Immunological impact of ramucirumab on tumor microenvironment in advanced gastric cancer.
First Author: Yosuke Togashi
Poster
2019 Genitourinary Cancers Symposium
Direct evidence of a clonal and tumor-directed T cell response to prostate cancer brachytherapy.
First Author: Scott Williams
Poster
2018 ASCO Annual Meeting
Immune profiling in a randomized phase II trial of acalabrutinib and pembrolizumab (PA) versus pembrolizumab (P) for patients with metastatic urothelial cancer (mUC).
First Author: Tian Zhang
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
A preclinical study of tumor-infiltrating lymphocytes in NSCLC.
First Author: Lorenzo Federico